Sign up to save your podcasts
Or
Share The FDA's Gene-Therapy Reversal and the Exit of Vinay Prasad
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
The FDA's Gene-Therapy Reversal and the Exit of Vinay Prasad
A top official at the Food and Drug Administration steps down after the agency changes course on a treatment for Duchenne muscular dystrophy. What does this episode say about the Trump Administration's approach toward drug development and innovation? Plus, Robert F. Kennedy Jr. says he plans to overhaul the National Vaccine Injury Compensation Program.
Learn more about your ad choices. Visit megaphone.fm/adchoices
View all episodes
By Paul Gigot, The Wall Street Journal
4.2
27142,714 ratings
A top official at the Food and Drug Administration steps down after the agency changes course on a treatment for Duchenne muscular dystrophy. What does this episode say about the Trump Administration's approach toward drug development and innovation? Plus, Robert F. Kennedy Jr. says he plans to overhaul the National Vaccine Injury Compensation Program.
Learn more about your ad choices. Visit megaphone.fm/adchoices
More shows like WSJ Opinion: Potomac Watch
View all
WSJ Your Money Briefing
1,722 Listeners
WSJ What’s News
4,356 Listeners
WSJ Tech News Briefing
1,636 Listeners
Law Talk With Epstein, Yoo & Cooke
696 Listeners
The Commentary Magazine Podcast
5,162 Listeners
The Editors
4,865 Listeners
WSJ Minute Briefing
670 Listeners
Bold Names
1,452 Listeners
Uncommon Knowledge
2,034 Listeners
The McCarthy Report
2,833 Listeners
The Journal.
6,083 Listeners
GoodFellows: Conversations from the Hoover Institution
690 Listeners
Bad Bets
1,322 Listeners
Honestly with Bari Weiss
8,787 Listeners
WSJ Opinion: Free Expression
607 Listeners
As We Work
151 Listeners
WSJ's Take On the Week
146 Listeners
All Things with Kim Strassel
161 Listeners